Affinage

Showing NCOA1 — SRC1 is a alias.

NCOA1

Nuclear receptor coactivator 1 · UniProt Q15788

Length
1441 aa
Mass
156.8 kDa
Annotated
2026-06-10
44 papers in source corpus 18 papers cited in narrative 18 extracted findings
Cross-family judge vs UniProt: Affinage preferred faithfulness: 6/6 claims corpus-supported (100%)

Mechanistic narrative

Synthesis pass · prose summary of the discoveries below

NCOA1 (SRC-1) is a transcriptional coactivator that bridges sequence-specific transcription factors to histone acetyltransferase machinery to amplify defined gene programs (PMID:24769444, PMID:12954634). It recognizes LXXLL motifs in the transactivation domains of partner factors through its N-terminal bHLH/PAS-B domain; crystallographic and mutagenesis work define a hydrophobic, surface-complementary interface that recognizes the STAT6 LXXLL helix and its flanking residues with specificity not shared by NCOA2 or NCOA3 (PMID:12138096, PMID:14757047, PMID:18464232). Through this mode it coactivates STAT6 and STAT5 in cytokine- and prolactin-driven transcription, cooperating with p300/CBP and the glucocorticoid receptor (PMID:11574547, PMID:12954634). NCOA1 engagement with STAT6 is gated by phosphorylation state: PP2A-mediated dephosphorylation is required for the interaction, while CDK phosphorylation inhibits it, coupling coactivation to cell-cycle position (PMID:21148148). NCOA1 assembles with acetyltransferases and DNA-binding factors into promoter-bound complexes that drive distinct outputs — with c-Fos and HIF1α at the CSF1 and VEGFa promoters to promote breast cancer metastasis, macrophage recruitment, and tumor angiogenesis (PMID:24769444, PMID:26287601); with EP300 to enhance H3K27 acetylation at the VEGFA promoter in glioma angiogenesis (PMID:41921814); with CBP and NF-κB at proinflammatory cytokine promoters (PMID:35339471); and with p300 and Runx2 to transactivate MMP genes, an output restrained by HERC3-mediated ubiquitination and degradation of NCOA1 (PMID:36878279). In metabolic physiology, NCOA1 acts cell-autonomously with GATA3 to drive UCP1 and thermogenic beiging of female subcutaneous adipocytes (PMID:41559022), and cooperates with NCOA3 to support placental labyrinth morphogenesis and embryo survival (PMID:20685850).

Mechanistic history

Synthesis pass · year-by-year structured walk · 15 steps
  1. 2001 High

    Established that NCOA1 is a selective coactivator for STAT6, defining a partner outside the classical nuclear-receptor sphere and localizing the contact to its N-terminal region.

    Evidence GST pulldown, co-IP, transactivation reporters and dominant-negative overexpression in mammalian cells

    PMID:11574547

    Open questions at the time
    • Did not resolve the precise binding motif or structural basis
    • Specificity over other STATs shown only at the family level
  2. 2002 High

    Identified the LXXLL motif in the STAT6 transactivation domain as the determinant docking onto the NCOA1 PAS-B domain, unifying STAT recognition with the nuclear-receptor coactivation paradigm.

    Evidence GST pulldown with LXXLL peptides/blocking antibodies, LXXLL mutagenesis, and endogenous eotaxin-3 activation

    PMID:12138096

    Open questions at the time
    • Atomic geometry of the interface not yet determined
    • Generality of LXXLL use across other NCOA1 partners untested here
  3. 2003 High

    Extended NCOA1 coactivation to STAT5a/b in prolactin signaling and showed cooperative action with p300/CBP and the glucocorticoid receptor, indicating combinatorial assembly on hormone-responsive promoters.

    Evidence Co-IP, domain deletion/mutagenesis, beta-casein promoter transactivation assays

    PMID:12954634

    Open questions at the time
    • STAT5 binding motif defined only as a short helical element
    • Endogenous gene targets beyond beta-casein not mapped
  4. 2004 High

    Provided the atomic-resolution basis for NCOA1 partner selectivity, showing the STAT6 LXXLL helix binds PAS-B through hydrophobic surface complementarity not reproduced by NCOA2/NCOA3.

    Evidence X-ray crystallography of the NCOA1 PAS-B / STAT6 LXXLL complex

    PMID:14757047

    Open questions at the time
    • Structures with other transcription-factor partners not solved
    • Does not address regulation of the interaction in cells
  5. 2008 Medium

    Refined the binding determinants beyond the core motif, showing LXXLL-flanking residues contribute energetically and that optimizing knobs-into-holes contacts raises affinity.

    Evidence Peptide binding assays and SAR of LXXLL-flanking residues

    PMID:18464232

    Open questions at the time
    • Single-lab biochemistry
    • Cellular consequence of affinity tuning not tested
  6. 2010 Medium

    Showed the NCOA1/STAT6 interaction is dynamically gated by phosphorylation — PP2A dephosphorylation enables it, CDK phosphorylation blocks it — linking coactivation to cell-cycle state.

    Evidence Co-IP with phosphatase and CDK inhibitors, cell-cycle synchronization, STAT6 target gene assays

    PMID:21148148

    Open questions at the time
    • Specific phosphosites on NCOA1 not mapped
    • Single lab; whether the same control applies to other partners unknown
  7. 2010 High

    Demonstrated an in vivo developmental requirement: NCOA1 acts redundantly with NCOA3 in placental labyrinth morphogenesis, with double knockout causing embryonic lethality.

    Evidence Single and double knockout mice, placental histology, gene expression analysis

    PMID:20685850

    Open questions at the time
    • Direct target genes in trophoblast not defined
    • NCOA1-specific (non-redundant) contribution not isolated
  8. 2015 High

    Defined NCOA1 as a driver of breast cancer metastasis and tumor angiogenesis by recruiting to AP-1 (c-Fos) and HIF1α promoter elements to transactivate CSF1 and VEGFa.

    Evidence MMTV-hNCOA1 transgenic and Ncoa1 knockout mice, ChIP at CSF1 and VEGFa promoters, knockdown, Matrigel angiogenesis and VEGFa rescue

    PMID:24769444 PMID:26287601

    Open questions at the time
    • How NCOA1 simultaneously bridges c-Fos and HIF1α mechanistically unresolved
    • Acetyltransferase partner at these promoters not identified in these studies
  9. 2016 Medium

    Placed NCOA1 in an AR-dependent prostate cancer migration program by showing its knockdown derepresses PRKD1 only in AR-positive cells and that PRKD1 inhibition rescues the migratory phenotype.

    Evidence siRNA knockdown, proliferation and Boyden-chamber assays, microarray, PRKD1 inhibitor epistasis

    PMID:27255895

    Open questions at the time
    • Direct AR/NCOA1 occupancy at PRKD1 not shown
    • Single lab
  10. 2017 High

    Validated the NCOA1 PAS-B pocket as a druggable target by disrupting the NCOA1/STAT6 interaction with a stapled helical peptide, confirmed structurally and functionally.

    Evidence Stapled peptide synthesis, PPI disruption and STAT6 reporter assays, crystal structure of peptide-NCOA1 complex

    PMID:29090910

    Open questions at the time
    • In vivo efficacy not addressed
    • Selectivity over other NCOA1 partner interactions not profiled
  11. 2017 Medium

    Expanded NCOA1's partner repertoire to RORγ, showing STAT3 promotes assembly of a RORγ-NCOA1 complex driving IL-17 transcription.

    Evidence Co-IP of RORγ-STAT3 and RORγ-NCOA1, shRNA knockdown, dominant-negative STAT3 and Stattic, IL-17 readout (with PPARγ co-factor shift in a separate adipocyte study)

    PMID:28579428 PMID:31133421

    Open questions at the time
    • Whether STAT3 bridges NCOA1 directly or indirectly unclear
    • PPARγ cofactor-shift finding rests on a single Co-IP
  12. 2022 Medium

    Defined an NCOA1-CBP-NF-κB complex on cytokine promoters and showed NCOA1 itself is transcriptionally upregulated via LPS-driven DNMT1 inhibition and promoter demethylation in inflammatory cardiac injury.

    Evidence Co-IP, ChIP at cytokine promoters, DNA-methylation analysis, small-molecule (PSSM2126) disruption of NCOA1-CBP in an EIMD mouse model

    PMID:35339471

    Open questions at the time
    • Direct DNA-binding partner directing NCOA1 to specific promoters not fully resolved
    • Single lab
  13. 2023 Medium

    Identified HERC3 as the E3 ligase controlling NCOA1 abundance, with accumulated NCOA1 assembling a p300-Runx2 complex that transactivates MMP genes in disc degeneration.

    Evidence Ubiquitination assay, co-IP/MS of the NCOA1-p300-Runx2 complex, RT-qPCR, SMTNP-191 small molecule in an aged-mouse IDD model

    PMID:36878279

    Open questions at the time
    • Ubiquitination site(s) on NCOA1 not mapped
    • Single lab
  14. 2026 High

    Established a sex-specific, cell-autonomous metabolic role: NCOA1 cooperates with GATA3 to drive UCP1 and beiging of female subcutaneous fat, with loss causing obesity and a male-like fat distribution.

    Evidence Adipocyte-specific NCOA1 knockout mice, cold/adrenergic challenge, UCP1 and mitochondrial gene profiling, metabolic phenotyping

    PMID:41559022

    Open questions at the time
    • Molecular basis of the GATA3-NCOA1 interaction not structurally defined
    • Source of sex specificity not mechanistically resolved
  15. 2026 Medium

    Showed EP300 forms a complex with NCOA1 that stabilizes its nuclear localization and synergistically increases H3K27ac at the VEGFA promoter to promote glioma angiogenesis, reinforcing the NCOA1-acetyltransferase VEGFA axis.

    Evidence Co-IP, nuclear-cytoplasmic fractionation, H3K27ac ChIP at VEGFA promoter, EP300 perturbation, endothelial assays

    PMID:41921814

    Open questions at the time
    • Mechanism of EP300-dependent nuclear stabilization of NCOA1 unclear
    • Single lab

Open questions

Synthesis pass · forward-looking unresolved questions
  • How upstream signals select which NCOA1-acetyltransferase-transcription factor complex assembles in a given cell type, and how phosphorylation, ubiquitination, and partner availability are integrated to direct the choice, remains unresolved.
  • No unified model linking NCOA1 post-translational state to partner choice
  • Structural data limited to the PAS-B/STAT6 interface
  • Endogenous genome-wide occupancy across tissues not mapped

Mechanism profile

Synthesis pass · controlled-vocabulary classification · explore literature graph →
Molecular activity
GO:0060090 molecular adaptor activity 5 GO:0140110 transcription regulator activity 5 GO:0098772 molecular function regulator activity 4
Localization
GO:0005634 nucleus 4 GO:0000228 nuclear chromosome 3
Pathway
R-HSA-162582 Signal Transduction 4 R-HSA-1643685 Disease 4 R-HSA-74160 Gene expression (Transcription) 4 R-HSA-168256 Immune System 3 R-HSA-1430728 Metabolism 2
Partners
CREBBPEP300FOSGATA3HIF1ARORCSTAT5ASTAT6
Complex memberships
NCOA1-CBP-NF-κB complexNCOA1-EP300 complexNCOA1-p300-Runx2 complex

Evidence

Reading pass · 18 per-paper findings extracted from the source corpus
Year Finding Method Journal Conf PMIDs
2001 NCOA1 (NCoA-1) acts as a coactivator for STAT6 by directly interacting with the C-terminal transactivation domain of STAT6 via its N-terminal region. The N-terminal part of NCOA1 interacts specifically with STAT6 but not with other STAT family members. Overexpression of this NCOA1 domain has a dominant-negative inhibitory effect on STAT6-mediated transactivation, demonstrating the essential role of this interaction. GST pulldown, mammalian cell co-immunoprecipitation, transactivation reporter assays, dominant-negative overexpression The Journal of biological chemistry High 11574547
2002 An LXXLL motif in the STAT6 transactivation domain mediates the specific interaction with the NCoA-1 PAS-B domain. Mutagenesis of the LXXLL motif eliminated STAT6/NCOA1 interaction both in vitro and in vivo, and strongly diminished IL-4-regulated activation of the endogenous STAT6 target gene eotaxin-3. GST pulldown with LXXLL peptides and blocking antibodies, LXXLL mutagenesis, endogenous target gene activation assay The Journal of biological chemistry High 12138096
2003 NCOA1 is a coactivator for both STAT5a and STAT5b in prolactin-dependent gene expression. Both the activation domain 1 and the amino-terminal bHLH/PAS domain of NCOA1 are required for STAT5 coactivation. The bHLH/PAS domain mediates direct interaction with STAT5a in cells. A three-amino-acid motif in an alpha-helical region of the STAT5a transactivation domain is essential for NCoA-1 binding. NCOA1 and p300/CBP cooperatively enhance STAT5a-mediated transactivation and NCOA1 is involved in the synergistic action of the glucocorticoid receptor and STAT5a on the beta-casein promoter. Co-immunoprecipitation, transactivation reporter assays, domain deletion and mutagenesis, beta-casein promoter assays The Journal of biological chemistry High 12954634
2004 Crystal structure of the NCOA1 PAS-B domain in complex with the STAT6 LXXLL motif was determined. The amphipathic alpha-helical STAT6 LXXLL motif binds predominantly through hydrophobic interactions to NCOA1 PAS-B. A single NCOA1 PAS-B residue makes hydrophilic contacts with the STAT6 peptide. STAT6 interacts only with the PAS-B domain of NCOA1 and not with homologous regions of NCOA2 or NCOA3, with specificity determined largely by surface complementarity between hydrophobic faces. X-ray crystallography (crystal structure determination) Journal of molecular biology High 14757047
2008 Energetically important contacts between STAT6 and NCOA1 extend to residues flanking the LXXLL motif, including residues in the sequence LLPPTEQDLTKLL. Optimizing knobs-into-holes contacts on the surface of the STAT6-derived peptide significantly improves affinity for NCOA1, revealing the molecular basis of binding specificity. Peptide binding assays, structure-activity relationship (SAR) analysis of LXXLL-flanking residues Chembiochem Medium 18464232
2010 Dephosphorylation of NCOA1 by PP2A phosphatase is essential for NCOA1 interaction with STAT6 and for IL-4-dependent transcriptional activation. Cyclin-dependent kinases phosphorylate NCOA1 to inhibit its interaction with STAT6, and cells arrested at G1/S show enhanced NCOA1 phosphorylation. Simultaneous inhibition of phosphatase and CDK activity rescues the NCOA1/STAT6 interaction, linking transcriptional coactivation to cell cycle regulation. Co-immunoprecipitation, phosphatase inhibitor treatment, CDK inhibitor treatment, cell cycle synchronization, STAT6 target gene activation assays Nucleic acids research Medium 21148148
2010 NCOA1 and NCOA3 cooperatively regulate placental morphogenesis and embryo survival. Double knockout of NCOA1 and NCOA3 in mice causes embryonic lethality by E13.5 with placental labyrinth defects including reduced maternal blood sinuses, fetal capillaries, and abnormal trophoblast differentiation, while single knockouts survive. NCOA1 and NCOA3 are expressed in the labyrinth and regulate expression of TGFβ-, PPARβ-, and PPARγ-regulated genes and glucose transporters (GLUT1, Cx26). Double knockout mouse generation, histological analysis of placenta, gene expression analysis Molecular endocrinology High 20685850
2014 NCOA1 promotes breast cancer metastasis by directly upregulating CSF1 (colony-stimulating factor 1) expression. NCOA1 and c-Fos are recruited to a functional AP-1 site in the CSF1 promoter, driving CSF1 transcription to enhance macrophage recruitment and lung metastasis. Silencing NCOA1 reduces CSF1 expression and decreases macrophage recruitment and cancer cell metastasis. MMTV-hNCOA1 transgenic mice, chromatin immunoprecipitation (ChIP) at CSF1 AP-1 promoter site, NCOA1 knockdown with metastasis and macrophage recruitment readouts Cancer research High 24769444
2015 NCOA1 promotes breast tumor angiogenesis by simultaneously associating with c-Fos at the AP-1 site (bp -938) and with HIF1α at the HIF1α-binding element (bp -979) of the VEGFa promoter, upregulating VEGFa transcription. Ncoa1 knockout reduces microvascular density in mammary tumors, while NCOA1 overexpression increases it. VEGFa treatment rescues the angiogenic defect caused by NCOA1 knockdown. ChIP at VEGFa promoter AP-1 and HIF1α sites, Ncoa1 knockout and NCOA1-overexpressing mouse models, Matrigel plug angiogenesis assay, VEGFa rescue experiment Oncotarget High 26287601
2016 NCOA1 knockdown in AR-positive prostate cancer cells reduces proliferation and strongly decreases migration and invasion. NCOA1 knockdown upregulates PRKD1 in AR-positive cells but not in AR-negative cells. Inhibition of PRKD1 reverses the reduced migratory potential caused by NCOA1 knockdown, placing PRKD1 downstream of the AR/NCOA1 axis in the regulation of cellular migration. NCOA1 siRNA knockdown, [3H]-thymidine incorporation proliferation assay, Boyden chamber migration/invasion assay, cDNA microarray transcriptome analysis, PRKD1 inhibitor epistasis Endocrine-related cancer Medium 27255895
2017 A cell-permeable stapled helical peptide targeting NCOA1 disrupts the NCOA1/STAT6 protein-protein interaction and represses STAT6-mediated transcription. The crystal structure of the stapled peptide in complex with NCOA1 was determined, confirming the binding mode. Stapled peptide synthesis, NCOA1/STAT6 interaction disruption assay, STAT6 transcriptional reporter assay, X-ray crystallography of stapled peptide-NCOA1 complex Journal of the American Chemical Society High 29090910
2017 Biochanin A enhances the interaction between NCOA1 (SRC-1) and PPARγ while reducing NCOA3 (SRC-3) levels, shifting co-factor selectivity of PPARγ and reducing lipid accumulation in pre-adipocytes. Co-immunoprecipitation, immunoblot, qPCR in 3T3-L1 pre-adipocyte cells treated with biochanin A Journal of infection and public health Low 31133421
2017 Biochanin A promotes STAT3-mediated recruitment of NCOA1 to RORγ, enhancing RORγ-dependent IL-17 transcription. Stable knockdown of either RORγ or STAT3 cancels biochanin A-induced IL-17 upregulation. A dominant negative STAT3 mutant or the STAT3 inhibitor Stattic disrupts the biochanin A-induced RORγ-NCOA1 complex. Co-immunoprecipitation of RORγ-STAT3 and RORγ-NCOA1 complexes, stable shRNA knockdown, dominant-negative STAT3 overexpression, STAT3 inhibitor treatment, IL-17 expression assay Biochemical and biophysical research communications Medium 28579428
2022 NCOA1 forms a transcriptional complex with CBP and NF-κB subunits that binds to promoters of proinflammatory cytokine genes to activate their expression in endotoxin-induced myocardial dysfunction. LPS inhibits DNMT1, decreasing DNA methylation at a CpG island on the NCOA1 promoter and causing NCOA1 overexpression. A small molecule, PSSM2126, identified by yeast-based screening, blocks NCOA1-CBP interaction in vitro and in vivo, alleviating inflammation and improving cardiac function. Co-immunoprecipitation of NCOA1-CBP-NF-κB complex, ChIP at cytokine gene promoters, DNMT1/DNA methylation analysis, small molecule screening, PSSM2126 treatment in EIMD mouse model Experimental cell research Medium 35339471
2023 NCOA1 accumulates upon HERC3 E3 ubiquitin ligase deficiency, as HERC3 normally ubiquitinates NCOA1 for degradation. Accumulated NCOA1 assembles with histone acetyltransferase p300 and Runx2 to form a complex that transactivates MMP gene expression, promoting extracellular matrix degradation in intervertebral disc degeneration. A small molecule SMTNP-191 targeting the NCOA1-p300 interaction suppresses MMP expression and attenuates disc degeneration in aged mice. Ubiquitination assay, co-immunoprecipitation and mass spectrometry to identify the NCOA1-p300-Runx2 complex, immunoblot, RT-qPCR, small molecule screening, aged mouse IDD model Life sciences Medium 36878279
2026 NCOA1 has a cell-autonomous role in promoting beiging of subcutaneous white adipocytes by directly regulating the thermogenic factor UCP1 and sex-dependent mitochondrial gene networks. Acting together with GATA3, NCOA1 establishes elevated basal thermogenic tone in female subcutaneous fat. Female mice lacking NCOA1 in subcutaneous adipocytes develop obesity, glucose intolerance, and a male-like fat distribution with increased visceral fat and reduced beige adipocytes. Adipocyte-specific NCOA1 knockout mouse model, cold and adrenergic stimulation assays, UCP1 expression measurement, metabolic phenotyping, co-factor interaction analysis with GATA3 Nature communications High 41559022
2026 EP300 forms a nuclear transcriptional co-activator complex with NCOA1 that stabilizes NCOA1 nuclear localization and synergistically enhances VEGFA expression by increasing H3K27 acetylation at the VEGFA promoter, promoting glioma angiogenesis. Co-immunoprecipitation of EP300-NCOA1 complex, nuclear-cytoplasmic fractionation, H3K27ac ChIP at VEGFA promoter, EP300 overexpression/knockdown, endothelial functional assays Experimental cell research Medium 41921814
2025 IRF1 drives NCOA1 transcription in retinal ischemia-reperfusion: ChIP and dual-luciferase assays confirmed IRF1 directly binds the NCOA1 promoter and activates NCOA1 expression. Knockdown of either IRF1 or NCOA1 increases autophagy, inhibits M1-type microglial polarization, reduces inflammatory cytokines, and inhibits the Wnt/β-catenin pathway. The Wnt/β-catenin activator HLY78 partially reverses the effect of NCOA1 knockdown, placing NCOA1 upstream of Wnt/β-catenin. ChIP assay, dual-luciferase reporter assay, adeno-associated virus-mediated IRF1/NCOA1 knockdown in rat RIR model, western blot, ELISA, immunofluorescence Cellular signalling Medium 40096931

Source papers

Stage 0 corpus · 44 papers · ranked by NIH iCite citations
Year Title Journal Citations PMID
2016 Novel PAX3-NCOA1 Fusions in Biphenotypic Sinonasal Sarcoma With Focal Rhabdomyoblastic Differentiation. The American journal of surgical pathology 84 26371783
2020 Uterine Tumor Resembling Ovarian Sex Cord Tumor (UTROSCT): A Morphologic and Molecular Study of 26 Cases Confirms Recurrent NCOA1-3 Rearrangement. The American journal of surgical pathology 79 31464709
2003 NCoA-1/SRC-1 is an essential coactivator of STAT5 that binds to the FDL motif in the alpha-helical region of the STAT5 transactivation domain. The Journal of biological chemistry 63 12954634
2001 Transcriptional activation by STAT6 requires the direct interaction with NCoA-1. The Journal of biological chemistry 63 11574547
2004 Structure of the NCoA-1/SRC-1 PAS-B domain bound to the LXXLL motif of the STAT6 transactivation domain. Journal of molecular biology 61 14757047
2016 Leptin and insulin up-regulate miR-4443 to suppress NCOA1 and TRAF4, and decrease the invasiveness of human colon cancer cells. BMC cancer 58 27842582
2014 NCOA1 Directly Targets M-CSF1 Expression to Promote Breast Cancer Metastasis. Cancer research 54 24769444
2021 Supratentorial non-RELA, ZFTA-fused ependymomas: a comprehensive phenotype genotype correlation highlighting the number of zinc fingers in ZFTA-NCOA1/2 fusions. Acta neuropathologica communications 49 34389065
2002 An LXXLL motif in the transactivation domain of STAT6 mediates recruitment of NCoA-1/SRC-1. The Journal of biological chemistry 47 12138096
2010 The cooperative function of nuclear receptor coactivator 1 (NCOA1) and NCOA3 in placental development and embryo survival. Molecular endocrinology (Baltimore, Md.) 46 20685850
2020 SRF-FOXO1 and SRF-NCOA1 Fusion Genes Delineate a Distinctive Subset of Well-differentiated Rhabdomyosarcoma. The American journal of surgical pathology 40 32187044
2019 PRRX-NCOA1/2 rearrangement characterizes a distinctive fibroblastic neoplasm. Genes, chromosomes & cancer 32 31008539
2015 NCOA1 promotes angiogenesis in breast tumors by simultaneously enhancing both HIF1α- and AP-1-mediated VEGFa transcription. Oncotarget 30 26287601
2017 Targeted Inhibition of the NCOA1/STAT6 Protein-Protein Interaction. Journal of the American Chemical Society 27 29090910
2021 Ependymoma-like tumor with mesenchymal differentiation harboring C11orf95-NCOA1/2 or -RELA fusion: A hitherto unclassified tumor related to ependymoma. Brain pathology (Zurich, Switzerland) 25 33576087
2019 Betulinic acid lowers lipid accumulation in adipocytes through enhanced NCoA1-PPARγ interaction. Journal of infection and public health 20 31133421
2021 PRRX1-NCOA1-rearranged fibroblastic tumour: a clinicopathological, immunohistochemical and molecular genetic study of six cases of a potentially under-recognised, distinctive mesenchymal tumour. Histopathology 19 34272753
2015 CKMT1 and NCOA1 expression as a predictor of clinical outcome in patients with advanced-stage head and neck squamous cell carcinoma. Head & neck 19 26516695
2016 The AR/NCOA1 axis regulates prostate cancer migration by involvement of PRKD1. Endocrine-related cancer 17 27255895
2020 Detection of a somatic GREB1-NCOA1 gene fusion in a uterine tumor resembling ovarian sex cord tumor (UTROSCT). Gynecologic oncology reports 16 32964092
2017 Biochanin A enhances RORγ activity through STAT3-mediated recruitment of NCOA1. Biochemical and biophysical research communications 15 28579428
2023 NCOA1/2/3 rearrangements in uterine tumor resembling ovarian sex cord tumor: A clinicopathological and molecular study of 18 cases. Human pathology 14 36646185
2022 Spindle Cell Sarcoma of the Uterus Harboring MEIS1::NCOA1 Fusion Gene and Mimicking Endometrial Stromal Sarcoma. International journal of surgical pathology 12 35477326
2023 Accumulation of NCOA1 dependent on HERC3 deficiency transactivates matrix metallopeptidases and promotes extracellular matrix degradation in intervertebral disc degeneration. Life sciences 10 36878279
2022 Pigmented PRRX1::NCOA1-rearranged fibroblastic tumor: A rare morphologic variant of an emerging mesenchymal tumor. Journal of cutaneous pathology 10 35583270
2021 Expression, Purification and Characterization of CAR/NCOA-1 Tethered Protein in E. coli Using Maltose-Binding Protein Fusion Tag and Gelatinized Corn Starch. Biological & pharmaceutical bulletin 8 33390539
2017 NCOA1 is a novel susceptibility gene for multiple myeloma in the Chinese population: A case-control study. PloS one 8 28264017
2019 NCOA1-ALK: a novel ALK rearrangement in one lung adenocarcinoma patient responding to crizotinib treatment. OncoTargets and therapy 7 30799936
2022 The NCOA1-CBP-NF-κB transcriptional complex induces inflammation response and triggers endotoxin-induced myocardial dysfunction. Experimental cell research 6 35339471
2008 Molecular characterization of the NCoA-1-STAT 6 interaction. Chembiochem : a European journal of chemical biology 6 18464232
2024 PRRX1-fused mesenchymal neoplasm: A novel PRRX1::NCOA1 fusion transcript. Journal of cutaneous pathology 5 38986510
2023 Ependymoma-like tumor with mesenchymal differentiation (ELTMD) with ZFTA:NCOA1 fusion: A diagnostic challenge. Neuropathology : official journal of the Japanese Society of Neuropathology 5 37931917
2025 MEIS1::NCOA1 Primitive Spindle Cell Sarcoma of the Kidney : Report of 7 Cases of a Distinctive Clinicopathologic Entity. The American journal of surgical pathology 3 40160183
2010 Interaction of STAT6 with its co-activator SRC-1/NCoA-1 is regulated by dephosphorylation of the latter via PP2A. Nucleic acids research 2 21148148
2026 Leptin Drives Breast Cancer Aggressiveness Acting Through the Activation of the NCOA1/STAT3 Pathway. Medical sciences (Basel, Switzerland) 1 41562922
2025 IRF1 regulates autophagy and microglia polarization in retinal ischemia-reperfusion through NCOA1/Wnt/β-catenin signalling pathway. Cellular signalling 1 40096931
2025 A locally aggressive pelvic MEIS1::NCOA1 fusion sarcoma in a young adult female: a case report and review of the literature. Diagnostic pathology 1 40420135
2026 NCOA1 is a gatekeeper of the sexually dimorphic thermogenic activity of white adipose tissue. Nature communications 0 41559022
2026 EP300/NCOA1 complex drives glioma angiogenesis via H3K27 acetylation-dependent activation of VEGFA. Experimental cell research 0 41921814
2026 PRRX1::NCOA1 Rearranged Fibroblastic Tumour: A New Report With a Brief Literature Review of an Uncommon Neoplasm. International journal of surgical pathology 0 42141976
2026 Rhabdomyosarcoma With Alveolar Morphology and a Novel NCOA1::ZNF143 Fusion in a 4-Year-Old Girl: A Case Report. Genes, chromosomes & cancer 0 42222954
2025 Mesenchymal Stem Cell-conditioned Medium Attenuated CoCl2-induced Injury of Renal Tubular Epithelial Cells by Inhibiting NCOA1, HIF-1α, and Sox9. Current pharmaceutical design 0 39871565
2025 ZFTA::NCOA1/2-Rearranged Epithelioid Mesenchymal Tumor-A Phenotypically Distinct Myoepithelial-Like Neoplasm Epigenetically Overlapping With Chondroid Lipoma. Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 0 41270902
2004 Crystallization and preliminary crystallographic studies of the NCoA-1/SRC-1 PAS-B domain bound to the LXXLL motif of the STAT6 transactivation domain. Acta crystallographica. Section D, Biological crystallography 0 14993689

Missed literature

Know a paper Affinage missed for NCOA1? Flag it for the maintainers and the community.

No submissions yet.